Table 2 Demographic and clinical characteristics of the cohort as a whole and of the two genotype groups.
| Whole cohort (n = 59) | Met66 carriers (n = 13) | Val66/Val66 homozygotes (n = 46) | |
|---|---|---|---|
| Mean (SD) age (years) | 41 (13) | 38.3 (13.5) | 42.2 (12.8) |
| Sex F:M, n | 46:13 | 12:1 | 34:12 |
| Ethnicity, n (%) | |||
| Caucasian | 31 (53) | 7 (54) | 24 (52) |
| African‐American | 16 (27) | 1 (8) | 15 (33) |
| Asian | 3 (5) | 2 (15) | 1 (2) |
| Hispanic | 9 (15) | 3 (23) | 6 (13) |
| Mean (SD) education (years) | 14.9 (3.0) | 14.3 (3.7) | 15.2 (2.9) |
| Mean (SD) disease duration (years) | 13.8 (10.3) | 13.6 (9.1) | 13.7 (10.6) |
| Anti‐ds DNA Ab pos, n (%) | 32 (54) | 7 (54) | 25 (54) |
| SLEDAI⩽4, n (%) | 46 (78) | 11 (84) | 35 (76) |
| Mean (SD) Beck Depression Inventory Scale | 8 (8) | 5.0 (7.5) | 9.1 (8.3) |
| Mean (SD) current prednisone dose (mg) | 4.5 (6.3) | 3.6 (3.6) | 4.8 (6.9) |
Anti‐ds DNA Abs pos, anti‐double‐stranded DNA antibody positivity; F, female; M, male; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index.